文献速递系统性红斑狼疮

系统性红斑狼疮糖皮质激素撤药:缓解与低疾病活动度能否作为停药起点

Glucocorticoid withdrawal in systemic lupus erythematosus: are remission and low disease activity reliable starting points for stopping treatment? A real-life experience.
PubMed 文献 · RMD Open · 2019-06-11

该纵向队列研究纳入148例系统性红斑狼疮(SLE)患者,其中91例尝试撤减糖皮质激素,77例成功停药。撤药开始时多数患者处于完全或临床缓解,成功停药者疾病活动度更低、完全缓解比例更高;停药后中位1年记录到18次复发,复发者距上次复发时间更短。

要点

  • SLE患者糖皮质激素撤药可行,91例尝试者中77例成功停药。
  • 撤药前疾病活动度更低、完全缓解比例更高的患者更易停药成功。
  • 停药后复发者距上次疾病复发的时间更短,提示需长期缓解后再尝试停药。

核心结论

  • SLE患者撤减糖皮质激素是可实现的目标,宜在长期缓解或LLDAS后尝试停药以减少复发风险。

研究设计与样本

  • 6年纵向队列研究,148例SLE患者中91例尝试糖皮质激素撤药,记录撤药期间疾病活动、损伤、治疗及停药后复发情况。
  • 缓解定义采用欧洲共识DORIS标准,LLDAS采用亚洲太平洋狼疮协作组定义。

主要发现

  • 91例尝试撤药者中77例(84.6%)成功停用糖皮质激素。
  • 撤药开始时48.9%患者为完全缓解、39.6%为临床缓解。
  • 成功停药者疾病活动度显著更低,完全缓解比例更高(54.2%)。
  • 停药患者中记录到18次复发,中位复发时间1年。
  • 复发者距上次复发时间短于未复发者(均值0.93年 vs 6.0年,p<0.001)。

关键数值与推荐

  • 完全缓解比例:成功停药者54.2%,高于停药失败者。
  • 复发距上次复发时间:复发者均值0.93年 vs 未复发者6.0年,p<0.001。

临床怎么用

  • 对已获长期缓解或LLDAS的SLE患者可考虑尝试糖皮质激素撤药,并关注距上次复发时间较短者的复发风险。

局限性

  • 原文摘要未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the proportion of patients who have successfully withdrawn glucocorticoids (GCs) in a longitudinal cohort of patients with systemic lupus erythematosus (SLE) over a period of 6 years; to evaluate patient characteristics during GC withdrawal in relation to existing definitions of remission and Lupus Low Disease Activity State (LLDAS); and to evaluate the occurrence of flares after GC withdrawal. METHODS: Patients who attempted GC withdrawal were identified for the cohort, and the following information was assessed during withdrawal attempts: date of last disease flare, disease activity and damage and ongoing treatment. Information regarding the occurrence of disease flares after GC withdrawal was also recorded for patients who successfully stopped treatment.Definitions of remission were applied to GC withdrawal in line with European consensus criteria (Definitions of remission in SLE [DORIS]) and LLDAS in line with the Asian Pacific Lupus Consortium definition. RESULTS: 148 patients were involved in the study; GC withdrawal was attempted in 91 patients (61.5%) with 77 patients (84.6%) successfully stopping GCs. At the beginning of the GC reduction, the majority of patients were in complete or clinical remission (48.9% and 39.6%, respectively). Disease activity was significantly lower in patients who successfully stopped GCs, and the proportion of patients in complete remission was higher (54.2%) with respect to patients who failed in their attempt. Among patients who stopped GCs, 18 flares were recorded after a median of 1 year. The time period since the last flare was shorter in patients who experienced flares with respect to patients who did not flare (mean 0.93 years vs 6.0, p<0.001). CONCLUSIONS: GC withdrawal is an achievable goal in SLE and may be attempted after a long-term remission or LLDAS to protect the patient from disease flares.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Tani C, Elefante E, Signorini V, et al. Glucocorticoid withdrawal in systemic lupus erythematosus: are remission and low disease activity reliable starting points for stopping treatment? A real-life experience. RMD Open. 2019. PMID: 31275608. doi:10.1136/rmdopen-2019-000916

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。